

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (amended) A method for treating cancer in a patient in need of such treatment, the method comprising administering to the patient a combination of a therapeutically effective amount of a ~~MEK inhibitor~~ N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and a therapeutically effective amount of capecitabine.
2. (amended) The method of Claim 1, wherein ~~the MEK inhibitor~~ N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and capecitabine are administered simultaneously.
3. (amended) The method of Claim 1, wherein ~~the MEK inhibitor~~ N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide is administered before capecitabine.
4. (amended) The method of Claim 1, wherein capecitabine is administered before ~~the MEK inhibitor~~ N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.
5. (original) The method of Claim 1 wherein the cancer is brain, breast, lung, non-small cell lung, ovarian, pancreatic, prostate, renal, colon, cervical, acute leukemia, gastric, melanoma or combinations thereof.
6. (canceled)
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. (canceled)

Attorney Docket No. PC 20550A

12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (new) The method of Claim 1, wherein the cancer is colon cancer.
17. (new) A pharmaceutical composition comprising capecitabine, *N*-[(*R*)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and a pharmaceutically acceptable carrier.
18. (new) A kit comprising in one compartment a dosage of *N*-[(*R*)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and in another compartment a dosage of capecitabine.
19. (new) The kit of Claim 18 further comprising a blister pack containing separate formulations of a tablet or capsule form of *N*-[(*R*)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and a tablet form of capecitabine.
20. (new) The kit of Claim 18 comprising instructions for combination administration.